Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms
- PMID: 34098210
- PMCID: PMC8630075
- DOI: 10.1016/j.jsat.2021.108514
Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms
Abstract
Objective: The COVID-19 pandemic led to unprecedented temporary federal and state regulatory flexibilities that rapidly transformed medication for opioid use disorder (MOUD) treatment delivery. This study aimed to understand changes in treatment providers' care during COVID-19, provider experiences with the adaptations, and perceptions of which changes should be sustained long-term.
Methods: We conducted in-depth, semi-structured interviews with 20 New Jersey MOUD providers, purposively sampled to reflect diversity in provider setting, specialty, and other characteristics. Using a rapid analysis approach, we summarized content within interview domains and analyzed domains across participants for recurring concepts and themes.
Results: MOUD treatment practice changes taking place during the COVID-19 pandemic included a rapid shift from in-person care to telehealth, reduction in frequency of toxicology testing and psychosocial/counseling services, and modifications to prescription durations and take-home methadone supplies. Modifications to practice were positively received and reinforced a sense of autonomy for providers as well as enhancing the ability to provide patient-centered care. All respondents expressed support for making temporary regulatory flexibilities permanent, but differed in their implementation of the flexibilities and the extent to which they planned to modify their own practices long-term.
Conclusion: Findings support sustaining temporary regulatory and payment changes to MOUD practice, which may have improved treatment access and allowed for more flexible, individually tailored patient care. Few negative, unintended consequences were reported by providers, but more research is needed to evaluate the patient experience with changes to practice during the COVID-19 pandemic.
Keywords: Buprenorphine; COVID-19; Medication for addiction treatment; Medication for opioid use disorder; Methadone; Telehealth.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
None.
References
-
- Bean M. Becker’s hospital review. 2020. COVID-19 death rates by state: Dec. 18.https://www.beckershospitalreview.com/public-health/us-coronavirus-death... Retrieved December 18, 2020, from.
-
- Carlson R.G., Daniulaityte R., Silverstein S.M., Nahhas R.W., Martins S.S. Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose? The International Journal on Drug Policy. 2020;79:102722. doi: 10.1016/j.drugpo.2020.102722. - DOI - PMC - PubMed
-
- Center for Connected Health Policy Telehealth coverage policies in the time of COVID-19. 2020. https://www.cchpca.org/resources/covid-19-telehealth-coverage-policies Retrieved December 22, 2020, from.
-
- Center on Budget and Policy Priorities Tracking the COVID-19 recession's effects on food, housing, and employment hardships. 2020, December 16. https://www.cbpp.org/research/poverty-and-inequality/tracking-the-covid-... Retrieved December 18, 2020, from.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
